Oncology drugs

Keytruda

Merck & Co., Inc. · 24441 cited findings

Opdivo

Bristol-Myers Squibb Company · 17346 cited findings

Brukinsa

BeOne Medicines Ltd. · 6647 cited findings

Enhertu

Daiichi Sankyo Company, Limited · 5358 cited findings

Perjeta

Roche Holding AG · 4060 cited findings

Avastin

Roche Holding AG · 3962 cited findings

Yervoy

Bristol-Myers Squibb Company · 3811 cited findings

Kisqali

Novartis AG · 3796 cited findings

Ibrance

Pfizer Inc. · 3515 cited findings

Abraxane

Bristol-Myers Squibb Company · 3452 cited findings

Trodelvy

Gilead Sciences, Inc. · 3271 cited findings

Taxotere

Sanofi · 3154 cited findings

Faslodex

AstraZeneca PLC · 3067 cited findings

Imbruvica

AbbVie Inc. · 3029 cited findings

Krazati

Bristol-Myers Squibb Company · 3003 cited findings

Tevimbra

BeOne Medicines Ltd. · 2990 cited findings

Augtyro

Bristol-Myers Squibb Company · 2957 cited findings

Padcev

Astellas Pharma Inc. · 2672 cited findings

TEPMETKO

Merck KGaA · 2640 cited findings

JEMPERLI

GSK plc · 2635 cited findings

Venclexta

AbbVie Inc. · 2611 cited findings

Zytiga

Johnson & Johnson · 2472 cited findings

Lumakras

Amgen Inc. · 2434 cited findings

Adcetris

Takeda Pharmaceutical Company Limited · 2394 cited findings

Breyanzi

Bristol-Myers Squibb Company · 2364 cited findings

Stivarga

Bayer Aktiengesellschaft · 2227 cited findings

Calquence

AstraZeneca PLC · 2162 cited findings

Tukysa

Pfizer Inc. · 1986 cited findings

Lynparza

AstraZeneca PLC · 1983 cited findings

Zynyz

Incyte Corporation · 1967 cited findings

Welireg

Merck & Co., Inc. · 1883 cited findings

Tecentriq

Roche Holding AG · 1780 cited findings

VERZENIO

Eli Lilly and Company · 1780 cited findings

Rybrevant

Johnson & Johnson · 1758 cited findings

Voranigo

Servier · 1757 cited findings

Nubeqa

Bayer Aktiengesellschaft · 1747 cited findings

Talvey

Johnson & Johnson · 1706 cited findings

Tafinlar

Novartis AG · 1684 cited findings

Ojemda

Ipsen S.A. · 1595 cited findings

Retevmo

Eli Lilly and Company · 1566 cited findings

Pepaxti

Oncopeptides · 1554 cited findings

Kadcyla

Roche Holding AG · 1542 cited findings

Tecartus

Gilead Sciences, Inc. · 1536 cited findings

Abecma

Bristol-Myers Squibb Company · 1535 cited findings

Imdelltra

Amgen Inc. · 1527 cited findings

Imlunestrant

Eli Lilly and Company · 1527 cited findings

Bavencio

Merck B V · 1513 cited findings

Nexpovio

Stemline B V · 1457 cited findings

Alecensa

Roche Holding AG · 1384 cited findings

Velcade

Johnson & Johnson · 1376 cited findings

AKEEGA

Johnson & Johnson · 1327 cited findings

Zepzelca

Mar S A · 1323 cited findings

Truqap

AstraZeneca PLC · 1303 cited findings

Zykadia

Novartis AG · 1290 cited findings

Xospata

Astellas Pharma Inc. · 1276 cited findings

Tabrecta

Novartis AG · 1234 cited findings

Jaypirca

Eli Lilly and Company · 1208 cited findings

Tepkinly

AbbVie Inc. · 1135 cited findings

Carvykti

Johnson & Johnson · 1131 cited findings

Finlee

Novartis AG · 1108 cited findings

Opdualag

Bristol-Myers Squibb Company · 1095 cited findings

Imjudo

AstraZeneca PLC · 1057 cited findings

Orserdu

Stemline B V · 1039 cited findings

Qinlock

Deciphera B V · 963 cited findings

Sprycel

Bristol-Myers Squibb Company · 932 cited findings

Pemazyre

Incyte Corporation · 922 cited findings

Aumseqa

SFL · 910 cited findings

Rydapt

Novartis AG · 902 cited findings

Lazcluze

Johnson & Johnson · 872 cited findings

Minjuvi

Incyte Corporation · 853 cited findings

Tagrisso

AstraZeneca PLC · 847 cited findings

Erleada

Johnson & Johnson · 828 cited findings

Spexotras

Novartis AG · 797 cited findings

Vyloy

Astellas Pharma Inc. · 790 cited findings

Erbitux

Merck B V · 774 cited findings

Jevtana

Sanofi · 772 cited findings

Loqtorzi

Topalliance Biosciences · 763 cited findings

Lytgobi futibatinib

Otsuka Holdings Co., Ltd. · 762 cited findings

Braftovi

Pfizer Inc. · 754 cited findings

Xtandi

Astellas Pharma Inc. · 748 cited findings

Xeloda

Cheplapharm · 742 cited findings

Columvi

Roche Holding AG · 737 cited findings

Tibsovo

Servier · 706 cited findings

Hetronifly

Accord S L U · 690 cited findings

Adstiladrin

Ferring A S · 689 cited findings

Lynozyfic

Regeneron Pharmaceuticals, Inc. · 686 cited findings

Lonsurf

Otsuka Holdings Co., Ltd. · 625 cited findings

OPDIVO QVANTIG

Bristol-Myers Squibb Company · 618 cited findings

Phelinun

ADIENNE S.r.l. · 611 cited findings

Imdylltra

Amgen Inc. · 607 cited findings

Gazyvaro

Roche Holding AG · 594 cited findings

Odomzo

Sun Industries B V · 593 cited findings

Sarclisa

Sanofi · 587 cited findings

Vanflyta

Daiichi Sankyo Company, Limited · 585 cited findings

Lenvima

Eisai Co., Ltd. · 584 cited findings

Avapritinib

Blueprint Medicines B V · 581 cited findings

Teysuno

Nordic B V · 566 cited findings

Halaven

Eisai Co., Ltd. · 564 cited findings

Elrexfio

Pfizer Inc. · 562 cited findings

KEYTRUDA QLEX

Merck & Co., Inc. · 558 cited findings

Erlotinib

Cheplapharm · 556 cited findings

Tyverb

Novartis AG · 552 cited findings

Romvimza

Deciphera B V · 544 cited findings

Onivyde pegylated liposomal

Servier · 536 cited findings

Besponsa

Pfizer Inc. · 529 cited findings

Cabometyx

Ipsen S.A. · 529 cited findings

Zelboraf

Roche Holding AG · 519 cited findings

Lunsumio

Roche Holding AG · 501 cited findings

Rozlytrek

Roche Holding AG · 499 cited findings

Elahere

AbbVie Inc. · 490 cited findings

Phesgo

Roche Holding AG · 487 cited findings

Cejemly

Cstone · 473 cited findings

Balversa

Johnson & Johnson · 472 cited findings

Herceptin

Roche Holding AG · 452 cited findings

Giotrif

Boehringer Ingelheim · 448 cited findings

Cometriq

Ipsen S.A. · 439 cited findings

Nexavar

Bayer Aktiengesellschaft · 434 cited findings

Tepadina

Unknown MAH · 409 cited findings

Aucatzyl

Autolus · 405 cited findings

dabrafenib + trametinib

Novartis AG · 402 cited findings

Koselugo

AstraZeneca PLC · 398 cited findings

Lumykras

Amgen Inc. · 397 cited findings

Fruzaqla

Takeda Pharmaceutical Company Limited · 393 cited findings

Tivdak

Genmab A S · 392 cited findings

Tecvayli

Johnson & Johnson · 390 cited findings

Zynlonta

Swedish Orphan Biovitrum · 381 cited findings

Caprelsa

Esteve S A · 381 cited findings

Ninlaro

Takeda Pharmaceutical Company Limited · 373 cited findings

BLINCYTO

Amgen Inc. · 362 cited findings

Votrient

Novartis AG · 359 cited findings

Kimmtrak / tebentafusp

Immunocore · 355 cited findings

Trisenox

Teva B V · 346 cited findings

Fotivda

Recordati B V · 324 cited findings

Qarziba

Recordati B V · 316 cited findings

Ziihera

Jazz · 307 cited findings

Javlor

Pierre Fabre Medicament · 301 cited findings

Darzalex

Johnson & Johnson · 301 cited findings

Venclyxto

AbbVie Inc. · 297 cited findings

Imfinzi

AstraZeneca PLC · 294 cited findings

Ogsiveo

Merck B V · 292 cited findings

Afinitor

Novartis AG · 287 cited findings

Dacogen

Unknown MAH · 276 cited findings

Sutent

Pfizer Inc. · 275 cited findings

Yondelis

Johnson & Johnson · 269 cited findings

Inlyta axitinib

Pfizer Inc. · 265 cited findings

Erivedge

Roche Holding AG · 262 cited findings

Xalkori

Pfizer Inc. · 258 cited findings

Ledaga

Helsinn Birex · 249 cited findings

Retsevmo

Eli Lilly and Company · 246 cited findings

Zejula

GSK plc · 204 cited findings

Tarceva

Cheplapharm · 201 cited findings

Vectibix

Amgen Inc. · 198 cited findings

Targretin

H A C · 178 cited findings

Farydak

Secura Bio · 163 cited findings

Elzonris

Stemline B V · 142 cited findings

Onureg

Bristol-Myers Squibb Company · 142 cited findings

Cotellic

Roche Holding AG · 141 cited findings

Kisplyx

Eisai Co., Ltd. · 136 cited findings

Korjuny

Atnahs B V · 133 cited findings

Datroway

Daiichi Sankyo Company, Limited · 129 cited findings

Libtayo

Regeneron Pharmaceuticals, Inc. · 128 cited findings

Vidaza

Bristol-Myers Squibb Company · 127 cited findings

Tuznue

Prestige Biopharma · 119 cited findings

Degarelix

Ferring A S · 110 cited findings

Portrazza

Eli Lilly and Company · 103 cited findings

Empliciti

Bristol-Myers Squibb Company · 98 cited findings

Evoltra

Sanofi · 97 cited findings

Inaqovi

Otsuka Holdings Co., Ltd. · 87 cited findings

Glivec

Novartis AG · 77 cited findings

Zolsketil pegylated liposomal

Accord S L U · 68 cited findings

MabThera

Roche Holding AG · 62 cited findings

Lartruvo

Eli Lilly and Company · 61 cited findings

Decitabine

Unknown MAH · 54 cited findings

Lysodren

Esteve S A · 52 cited findings

Unituxin

United Therapeutics Corporation · 49 cited findings

Zaltrap

Sanofi · 45 cited findings

Tafinlar (dabrafenib) + trametinib

Novartis AG · 45 cited findings

Alimta

Eli Lilly and Company · 44 cited findings

Oncaspar

Servier · 33 cited findings

palbociclib

Pfizer Inc. · 31 cited findings